Latest Media Releases (Page 13) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Late-stage & registrational trial progress: -- TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) ...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - June 2023 (ASX:IIQ)

Highlights: -- Positive clinical data demonstrating SubB2M/CA15-3 test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) -- Post quarter ...read more

Immutep - 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

Next Science - Investor Presentation - Q2 2023 (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science - Appendix 4C - 30 June 2023 (ASX:NXS)

To view the appendix, download the attached PDF.

Next Science - Quarterly Activity Report - 30 June 2023 (ASX:NXS)

Highlights: -- 2QFY23 Product Sales (unaudited) increased 27% qoq and 71% yoy to US$5.6m -- Direct channel Product Sales increased 50% qoq and 258% yoy to US$4.3m -- 1HFY23 Unaudited Product Sa...read more

Paragon Care - Trading Update - FY23 Results (ASX:PGC)

Paragon Care Limited (PGC) has today updated its earnings guidance for the year ending 30 June 2023 (FY23). Based on the unaudited Accounts, PGC expects to deliver Underlying EBITDA of approximatel...read more

INOVIQ and Promega announce Global Joint Marketing Agreement (ASX:IIQ)

Melbourne, Australia and Madison, WI USA, 6 July 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a...read more

INOVIQ - SubB2M/CA15.3 Clinical Validation Data Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Application for quotation of securities - IMM (ASX:IMM)

To view the application, download the attached PDF.

Next Science - Market Update (ASX:NXS)

Sydney Australia Thursday, 29 June 2023: Next Science Limited (ASX: NXS) (Next Science or Company), a medical technology company focused on commercialising its proprietary XBIOTM suite of products t...read more

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disea...read more

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

INOVIQ - Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test (ASX:IIQ)

Highlights INOVIQ’s SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) The results of a comprehen...read more

Immutep completes underwritten retail entitlement offer (ASX:IMM)

On Wednesday, 31 May 2023, Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) announced a fully underwritten placement to institutional investors (Placement) and 1 for 7.6 pro rata ...read more

Viewing: 181 - 195 of 200 Previous | Next